Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  KOREA EXCHANGE (KOSDAQ)  >  Celltrion, Inc.    068270   KR7068270008

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( KRW)
Sales 2017 891 B
EBIT 2017 409 B
Net income 2017 321 B
Debt 2017 285 B
Yield 2017 0,01%
Sales 2018 1 191 B
EBIT 2018 582 B
Net income 2018 459 B
Debt 2018 99,6 B
Yield 2018 0,01%
P/E ratio 2017 42,88
P/E ratio 2018 30,33
EV / Sales2017 15,6x
EV / Sales2018 11,5x
Capitalization 13 609 089 M
More Financials
Company
Celltrion, Inc. engages in the development, manufacture, and distribution of pharmaceuticals.It operates through the Biopharmaceuticals, Chemical Drugs, and Others businesses.Its products include remsima and biosimilars.The company was founded on February 27, 1991 and is headquartered in Incheon,... 
More about the company
Surperformance© ratings of Celltrion, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on CELLTRION, INC.
06/22 CELLTRION : "Human Monoclonal Antibodies Derived from Human B Cells and Having N..
05/26 CELLTRION : Why biosimilars are changing the pharmaceutical industry
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
04/28 Celltrion wins Herceptin patent trials against Roche in Korea
04/07 CELLTRION : George Steuart Health partners with Celltrion Healthcare to launch f..
03/02 CELLTRION : Patent Issued for Human Monoclonal Antibodies Derived from Human B C..
02/20 PFIZER : Celltrion Healthcare & Pfizer’s biosimilar shows positive results..
2016 CELLTRION : New statement from European Crohn's and Colitis Organisation support..
2016 CELLTRION HEALTHCARE : Presents Positive Results for CT-P10, Biosimilar Rituxima..
2016 MONOCLONAL ANTIBODIES MARKET 2016-20 : Celltrion, Boehringer Ingelheim, Dr Reddy..
More news
Sector news : Biotechnology & Medical Research - NEC
07/26 Autos and energy firms boost European shares as earnings roll in, banks held ..
07/25DJCELGENE : Settles Lawsuit Over Improper Promotion of Cancer Drugs
07/25DJELI LILLY AND : to Delay Arthritis Drug Application -- Market Talk
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
More sector news : Biotechnology & Medical Research - NEC
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 128 122  KRW
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Wu-Sung Ki Co-Chief Executive Officer & Director
Hyung-Ki Kim Co-Chief Executive Officer & Director
Jung-Jin Seo Director
Dong-Il Kim Outside Director
Gyung-Ho Lee Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.12 153
INCYTE CORPORATION36.82%27 350
QUINTILES IMS HOLDINGS INC19.03%19 536
LONZA GROUP31.41%16 761
ALKERMES PLC4.34%8 884
QIAGEN NV17.91%7 892